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Punctate inner choroidopathy (PIC) is a rare idiopathic inﬂammatory disorder of the retina and choroid usually aﬀecting healthy,
young, myopic females and presenting with photopsia, paracentral scotomata, and blurred vision. It is characterized by yellow-
whitechorioretinallesionsconcentratedintheposteriorpole,novitritis,relapsinginﬂammatoryactivityoftheretinaandchoroid,
and frequent development of choroidal neovascular membranes. Here we describe a case in which spectral-domain optical coher-
ence tomography (SD-OCT) imaging was used to monitor outer retinal structure changes associated with recurrent PIC over
time. SD-OCT, which is both quantative and objective, provides an eﬃcient, non-invasive way to follow recurrent inﬂammatory
chorioretinal lesion activity, choroidal neovascular membrane development, and treatment response in patients with recurrent
PIC.
1. Report of a Case:
A 21-year-old white myopic female with a history of sym-
ptomaticpunctateinnerchoroidopathy(PIC)presentedwith
new photopsias and scotoma in her left eye for several days.
She had been symptomatic in her right eye for one year with
documented new chorioretinal lesion formation and de-
velopment of a choroidal neovascular membrane (CNVM)
successfully treated with photodynamic therapy (PDT), in-
travitreal triamcinolone, and intravitreal bevacizumab (Av-
astin, Genentech, South San Francisco, Calif). Past ocular
historywassigniﬁcantforherpetickeratitisforwhichshewas
taking acyclovir 400mg daily.
On exam, visual acuity was 20/20 OU with myopic cor-
rection.Anteriorchamberandvitreouswerewithoutinﬂam-
mation.Funduscopyshowedmultipleyellowish-whitechori-
oretinal lesions and a pigmented scar from the CNVM lo-
calized within the posterior pole in the right eye, and a
focal chorioretinal lesion with ﬂuid just nasal to the fovea in
her left eye (Figure 1). When compared to previous fundus
photos, the lesion in the left eye was new. No peripheral
lesions were present. Fluorescein Angiogram (FA) showed
focal leakage, left eye, consistent with CNVM. Indocyanine
green (ICG) showed hypoﬂuorescent spots corresponding
to the chorioretinal lesions consistent with PIC [1]i nb o t h
eyes, and a focal area of hyperﬂuorescence at the edge of the
hypoﬂuorescent spot in the left eye, suggesting a CNVM.
Spectralis spectral-domain optical coherence tomogra-
phy (SD-OCT) (Spectralis HRA; Heldelberg Engineering,
Heidelberg, Germany) of the left eye at the initial visit
showed retinal pigment epithelium (RPE) elevation with
surrounding intraretinal ﬂuid (IRF) consistent with CNVM
(Figure 2(b)). Two weeks after treatment with intravitreal
bevacizumab, SD-OCT showed resolution of IRF (Figure
2(d)).
Over the next 2 months, the patient continued to have
symptomatic photopsias in both eyes. Clinical exam contin-
ued to show no anterior chamber inﬂammation or vitritis.
She was placed on an extended oral prednisone taper. While
still on 30mg of oral prednisone, she experienced an acute2 Journal of Ophthalmology
Figure 1: Right and left fundus photos of patient with recurrent punctate inner choroidopathy. Right fundus shows multiple yellowish-
white chorioretinal lesions, some appear atrophic, localized to the posterior pole. Just inferior to the fovea is a pigmented scar from a
successfully treated choroidal neovascular membrane. The left fundus shows a new focal yellowish chorioretinal lesion with surrounding
ﬂuid not documented on previous fundus photographs.
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Figure 2: Spectralis spectral-domain optical coherence tomography (SD-OCT) images taken at the same location of both eyes over a 5.5-
monthperiodinapatientwithrecurrentpunctateinnerchoroidopathy.(a)and(b)Initialvisit.(b)Showsouterretinalirregularityandinner
retinal ﬂuid (IRF) from choroidal neovascular membrane (CNVM). (c) and (d) Followup two weeks later. After intravitreal bevacizumab
treatment, left eye, shows resolution of IRF (d). (e) and (f) Two months later shortly after stopping chronic antiviral therapy. The patient
experienced new photopsias, right eye, and SD-OCT revealed homogenous outer retinal thickening over chorioretinal lesions consistent
with recurrent inﬂammatory activity (e). (g) and (h) Three months later after treatment. Symptoms subsided, and outer retinal thickening
has resolved (g). Left eye shows no reoccurrence of CNVM (h).
increase in photopsias in her right eye. Four days earlier,
she had run out of oral acyclovir. SD-OCT was suggestive
of recurrent inﬂammatory lesion activity with new homoge-
neousouterretinalthickeningoverlyingchorioretinallesions
but with no IRF (Figure 2(e)). The patient was treated with
a higher dose of oral prednisone, oral valacyclovir (Valtrex,
GlaxoSmithKline, Research Triangle Park, NC, USA), and
two intravitreal bevacizumab injections over the next 2
months. Her symptoms resolved, and SD-OCT showed
improvement in thickening over the chorioretinal lesions.
Vision is still 20/20 OU.
2. Discussion
First described by Watzke et al. in 1984, PIC is a rare idi-
opathic inﬂammatory disorder of the retina and choroid us-
uallyaﬀectinghealthy,young,myopicfemalesandpresenting
with photopsia, paracentral scotomata, and blurred vision
[2]. Initial symptoms are usually unilateral although exam
shows bilateral disease [2, 4]. Clinically, yellow-white chori-
oretinal lesions ranging in size from 100 to 300 microns are
concentrated in the posterior pole and there is no vitreous
inﬂammation [3].Journal of Ophthalmology 3
Vision loss with PIC is usually secondary to development
of CNVMs which can occur in 40–76% of patients [2–5].
Recently, intravitreal anti vascular endothelial growth factor
(anti-VEGF) agents has been shown to be very eﬀective in
the treatment of CNVM associated with PIC [6–8]. SD-
OCT imaging in our patient documented a great treatment
response after intravitreal bevacizumab injection with reso-
lution of IRF just 2 weeks after treatment.
PIC is characterized by relapsing inﬂammatory activity
of the retina and choroid [9]. Unlike with CNVM where IRF
was visualized, SD-OCT showed a homogenous thickening
over the chorioretinal lesions with recurrent inﬂammatory
activity. In this patient, her recurrent PIC may be associated
with a viral etiology, as symptoms increased and SD-
OCT documented outer retinal changes suggesting recurrent
inﬂammatory activity shortly after cessation of chronic anti-
viral therapy. After restarting both immunosuppressive and
antiviral therapy, both symptoms and SD-OCT ﬁndings
improved.
SD-OCT gives excellent detail of outer retinal structures
in patients with PIC. In this patient with recurrent PIC,
SD-OCT imaging provided a quantitative and objective way
to monitor outer retinal structure changes associated with
CNVM development, treatment response, and recurrent in-
ﬂammatory chorioretinal lesion activity. Given it is noninva-
sive,SD-OCTmayprovetobeaveryeﬀectivewaytomonitor
and better understand pathology in patients with PIC who
develop CNVM and/or recurrent inﬂammatory activity.
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